Koers Medivir AB (publ) OTC Markets
Aandelen
MVRBF
SE0020181014
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 32,3 mln. 3,07 mln. 2,87 mln. | Omzet 2025 * | 52,05 mln. 4,95 mln. 4,63 mln. | Marktkapitalisatie | 349 mln. 33,2 mln. 31 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -75 mln. -7,14 mln. -6,67 mln. | Nettowinst (verlies) 2025 * | -92 mln. -8,76 mln. -8,18 mln. | EV/omzet 2024 * | 5,7 x |
Nettoliquiditeiten 2024 * | 165 mln. 15,67 mln. 14,64 mln. | Nettoliquiditeiten 2025 * | 245 mln. 23,32 mln. 21,77 mln. | EV/omzet 2025 * | 2 x |
K/w-verhouding 2024 * |
-5,65
x | K/w-verhouding 2025 * |
-2,46
x | Werknemers | 10 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 64,85% |
Recentste transcriptie over Medivir AB (publ)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jens Lindberg
CEO | Chief Executive Officer | 53 | 24-01-22 |
Director of Finance/CFO | 50 | 12-08-19 | |
Uli Alf Hacksell
CHM | Chairman | 74 | 03-05-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Uli Alf Hacksell
CHM | Chairman | 74 | 03-05-18 |
Director/Board Member | 68 | 03-05-18 | |
Yilmaz Mahshid
BRD | Director/Board Member | 45 | 26-05-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,15% | 124 mld. | |
+18,02% | 111 mld. | |
-12,75% | 23,17 mld. | |
+5,07% | 22,94 mld. | |
-39,94% | 17,42 mld. | |
-9,86% | 17,42 mld. | |
-14,97% | 16,9 mld. | |
+2,80% | 13,71 mld. | |
+27,39% | 11,82 mld. |